MIRM - Leadership updates

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Doug Sheehy, JD, as chief legal officer. Mr. Sheehy brings nearly two decades of experience leading global legal and compliance operations for biopharmaceutical companies. Mr. Sheehy was most recently chief legal officer and secretary at Sonoma Biotherapeutics, Inc., which is developing regulatory T cell therapies for autoimmune and inflammatory diseases. Prior to Sonoma, from 2016 to 2020, he served as general counsel and secretary for Aimmune Therapeutics, Inc., a biopharmaceutical company that specialized in the development and commercialization of treatments for life-threatening food allergies. Mr. Sheehy serv

- 2024 net product sales of approximately $336 million exceeds upper end of guidance range; preliminary and unaudited estimate - 2025 expected global net product sales of $420 million to $435 million - VISTAS study of volixibat in primary sclerosing cholangitis expected to complete enrollment in second half 2025; topline data expected 2026 Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today provided its preliminary and unaudited estimates for full-year 2024 net product sales, year-end cash balance, corporate updates, and full-year 2025 outlook. "2024 marked a significant year for Mirum as we accelerated our commercial business and achieved significant development milestones," said Chris

SAN MATEO, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today announced the appointments of two biotechnology industry leaders, Tim Walbert and Paul Hoelscher, to the board of directors of the Company, effective April 1, 2024. "We are fortunate to have Tim and Paul join us at this key stage as we prepare to initiate a pivotal, Phase 3 trial for our lead candidate denifanstat in MASH in the second half of 2024," said Dave Happel, CEO of Sagimet. "With his experience as CEO of publi

Se NodThera Ltd ("NodThera" or the "Company") NodThera Announces Appointment of Dr. Thomas Jaecklin as Chief Medical Officer BOSTON, MA, February 5, 2024 - NodThera, a leading clinical-stage biotech developing brain-penetrant NLRP3 inhibitors to treat chronic inflammatory diseases, today announces the appointment of Thomas Jaecklin, M.D., M.Sc., FMH as Chief Medical Officer (CMO), with effect from today. With more than 20 years of experience across global large pharma, biotech and academic medicine, Dr. Jaecklin is an accomplished late-stage drug development leader. He brings deep expertise across multiple therapy areas, including neuroscience and inflammation, with a strong track reco

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that in conjunction with the recent appointment of Joanne Quan, MD as Chief Medical Officer, the Compensation Committee of Mirum's Board of Directors approved an inducement grant of non-qualified stock options to purchase 75,000 shares of common stock and 37,500 restricted stock units ("RSUs") under Mirum's 2020 Inducement Plan. The Compensation Committee approved the awards as an inducement material to Dr. Quan's employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock option has an exercise price per share equal to $26.72 per share, Mirum's closing trading price on January 16, 2024, and will vest over four years, wi

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), today announced the appointment of Joanne Quan, MD as Chief Medical Officer. Dr. Quan will lead the global clinical development, clinical operations, and safety programs for Mirum's pipeline of programs addressing rare diseases. Dr. Quan was most recently Chief Medical Officer at Nuvig Therapeutics. Prior to Nuvig, she served in the same role at Modis Therapeutics, a company focused on rare genetic diseases (acquired by Zogenix, Inc. and subsequently UCB). Before Modis, she held clinical development leadership positions at Eiger Biopharmaceuticals, InterMune, Arena Pharmaceuticals, Bayhill Therapeutics, ALZA Corporation (Johnson and Johnson), Gen

- $186-188 million in total revenue and $178-180 million net product sales expected for 2023, preliminary and unaudited - LIVMARLI net products sales of $141-143 million expected for 2023, representing approximately 89% year-over-year growth, preliminary and unaudited Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today provided its preliminary and unaudited estimates for full-year 2023 revenue and net product sales, corporate updates, and full-year 2024 outlook. "2023 was a transformative year for Mirum as we cemented our position as a leader in rare disease and dramatically advanced our operating and financial scale. We expanded our reach and impact through strong global adoption of LIVM

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Eric Bjerkholt as chief financial officer (CFO). "Eric is an accomplished CFO bringing an outstanding track record in driving financial performance, business development, and operations management," said Chris Peetz, president and chief executive officer at Mirum. "Eric is joining at an important period of growth and global scale for Mirum, and it is a pleasure to have his experience and leadership at Mirum as we continue to execute on numerous initiatives across our rare disease franchises." Mr. Bjerkholt brings extensive business leadership experience from roles served in the biopharmaceutical industry. He co

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced that Tim Walbert has been appointed to the company's Board of Directors. In addition to Mr. Walbert's appointment, the company shared that Niall O'Donnell, Ph.D., a Mirum director since November 2018, has announced his plan to step down from the Board of Directors concurrent with the upcoming 2023 Annual Meeting of Stockholders expected to be held on June 12, 2023. Tim Walbert joins Mirum's board following a 15-year tenure as president, chief executive officer, and chairman of the board of Horizon Therapeutics, which he built from inception to a leading rare disease company. Horizon recently announced its intent to be acquired by A

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Lon Cardon, Ph.D., FMedSci, to its Board of Directors where he will also serve as a member of the Nominating and Governance Committee. Dr. Cardon brings nearly 30 years of extensive industry and academic experience in drug discovery and development. Dr. Cardon currently serves as president and chief executive officer of The Jackson Laboratory. Prior to this role, Dr. Cardon was chief scientific officer and chief scientific strategy officer at BioMarin. Before joining BioMarin, he was a senior vice president at GlaxoSmithKline, leading departments and divisions spanning genetics, molecular biology, computational bi

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of Saira Ramasastry to the Company's board of directors and as a member of the audit committee where she will bring to bear her more than 20 years of financial leadership. "Saira's extensive financial and strategic experience will be a tremendous complement to our board of directors as we seek to expand the reach and impact of LIVMARLI®, advance our development programs, and grow our rare disease pipeline," said Chris Peetz, president and chief executive officer of Mirum. "We have sought to comprise our Board with individuals of strong integrity, experience and judgment, and we believe Saira will be a great fit and v

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) today announced the appointment of industry veteran William C. Fairey to its Board of Directors. Mr. Fairey brings to Mirum significant experience in establishing commercial organizations within public companies, building markets, and launching novel therapeutics to treat specialty and rare and orphan diseases. Concurrent with the appointment of Mr. Fairey, Tiba Aynechi, Ph.D., has resigned from the Company's Board of Directors and her position on the Board's Compensation and Nominating and Corporate Governance Committees, respectively, effective August 19, 2021. Dr. Aynechi has been a valued Director since Mirum's inception in 2018. "Bill's exten

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced the appointment of Carol L. Brosgart, M.D., clinical professor of medicine, biostatistics and epidemiology, University of California, San Francisco, as an independent director to its Board of Directors. Dr. Brosgart currently serves as an industry consultant and scientific advisor, and as an independent director for several public and privately held biotechnology companies. “Dr. Brosgart is a visionary leader in development, advocacy and policy for advancing life-changing medicines,” said Chris Peetz, president and chief executive officer at Mirum. “We are thrilled to welcome Carol to

FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a biopharmaceutical company focused on the development and commercialization of a late-stage pipeline of novel therapies for debilitating liver diseases, today announced that on January 8, 2021, the Compensation Committee of Mirum’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 49,900 shares of common stock to five new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4). Each stock